Results 171 to 180 of about 150,813 (294)
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu +7 more
wiley +1 more source
Tumor Lysis Syndrome Triggered by Acalabrutinib in Chronic Lymphocytic Leukemia (CLL): Diagnostic and Therapeutic Implications. [PDF]
Fadi M +4 more
europepmc +1 more source
L1CAM Promotes the Infiltrative Properties of Patient‐Derived Glioblastoma Cells
In vivo validation of L1CAM‐mediated GBM infiltration. Orthotopic transplantation of L1CAM‐expressing GBM cells into mouse brains demonstrated that L1CAM significantly promotes tumor cell infiltration and expansion in the brain parenchyma, confirming its critical role in the aggressive progression of GBM.
Asako Katsuma +10 more
wiley +1 more source
Infection Masquerading As Spontaneous Tumor Lysis Syndrome. [PDF]
DeSalvo J, Rossetti AL.
europepmc +1 more source
Hypoxia exposure activates HIF‐2α, which binds to the Camk4 promoter to enhance RANKL‐mediated osteoclast differentiation, leading to aggravated alveolar bone resorption in periapical periodontitis. ABSTRACT Periapical periodontitis is one of the most common inflammatory bone destructive diseases. Epidemiological evidence suggests that hypoxia exposure,
Kang Gao +11 more
wiley +1 more source
Tumor Lysis Syndrome Induced by Selpercatinib in Rearranged During Transfection (RET) Fusion-Positive Non-Small-Cell Lung Cancer. [PDF]
Sagawa S, Tomoda Y, Shikama J, Awaya Y.
europepmc +1 more source
Summary Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce.
Patrick Schummer +10 more
wiley +1 more source
Tumor Lysis Syndrome After mFOLFOX6 Administration for Ascending Colon Cancer. [PDF]
Kano Y +8 more
europepmc +1 more source
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell +7 more
wiley +1 more source
Continuous hemodiafiltration during chemotherapy for acute kidney injury in spontaneous tumor lysis syndrome due to high-grade B-cell lymphoma: a case report. [PDF]
Kawamura N +10 more
europepmc +1 more source

